Novavax
NVAX
#5687
Rank
NZ$2.40 B
Marketcap
NZ$14.55
Share price
0.82%
Change (1 day)
25.30%
Change (1 year)

P/E ratio for Novavax (NVAX)

P/E ratio as of November 2026 (TTM): -5.24

According to Novavax's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.23684. At the end of 2025 the company had a P/E ratio of 2.45.

P/E ratio history for Novavax from 2001 to 2026

PE ratio at the end of each year

Year P/E ratio Change
20252.45-137.52%
2024-6.54
2022-1.24-79.84%
2021-6.14-62.59%
2020-16.42239.61%
2019-0.7019-80.73%
2018-3.6485.12%
2017-1.9760.9%
2016-1.22-91.4%
2015-14.2-13.67%
2014-16.5

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Novartis
NVS
29.6-664.54%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
39.5-854.67%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
25.1-579.42%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
16.9-422.40%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
-5.52 5.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
-6.33 20.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Agenus
AGEN
3.17-160.50%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
-2.70-48.36%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
-5.41 3.26%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
-1.09-79.16%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.